glp 1 and crohn's disease Frontiers GI and Hepatology News -

Learn about clinical benefits, dosing strategies, safety considerations, and who should consider this evidence-based combination therapy for superior glycemic management and weight loss.

Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.

The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.

WEEKS 35 EXPECTATIONS: As gut health and microbiome continue to improve, many users begin to notice more consistent digestive comfort and appetite awareness within 35 weeks of regular use

Thats why the FDA gives it a boxed warning

The fermentation of fiber in the gut leads to the production of short-chain fatty acids, which can stimulate GLP-1 secretion